First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report.
作者信息
Amabile E, Fazio F, Martelli M, Petrucci M T
机构信息
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, Italy.
出版信息
Leuk Res Rep. 2024 Nov 26;22:100491. doi: 10.1016/j.lrr.2024.100491. eCollection 2024.
Abstract
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme.
摘要
相似文献
1
First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report.
Leuk Res Rep. 2024 Nov 26;22:100491. doi: 10.1016/j.lrr.2024.100491. eCollection 2024.
2
Essential thrombocythemia as an initial presentation of polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome with complete response to the bortezomib, cyclophosphamide, dexamethasone regimen: a case report.
J Med Case Rep. 2025 Jul 1;19(1):301. doi: 10.1186/s13256-025-05338-4.
3
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.
Cochrane Database Syst Rev. 2008 Oct 8(4):CD006828. doi: 10.1002/14651858.CD006828.pub2.
4
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.
Cochrane Database Syst Rev. 2012 Jun 13;2012(6):CD006828. doi: 10.1002/14651858.CD006828.pub3.
5
Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature.
Front Oncol. 2025 Jun 6;15:1570981. doi: 10.3389/fonc.2025.1570981. eCollection 2025.
6
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.
J Med Case Rep. 2022 Aug 18;16(1):311. doi: 10.1186/s13256-022-03552-y.
7
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
8
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.
10
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
本文引用的文献
1
POEMS syndrome: Update on diagnosis, risk-stratification, and management.
Am J Hematol. 2023 Dec;98(12):1934-1950. doi: 10.1002/ajh.27081. Epub 2023 Sep 21.
2
Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.
J Med Case Rep. 2022 Aug 18;16(1):311. doi: 10.1186/s13256-022-03552-y.
3
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis.
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):297-304. doi: 10.1016/j.clml.2021.10.007. Epub 2021 Oct 31.
4
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
5
Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- A Systematic Review.
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e26-e33. doi: 10.1016/j.clml.2021.07.033. Epub 2021 Aug 2.
6
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome.
Hemasphere. 2020 May 21;4(3):e381. doi: 10.1097/HS9.0000000000000381. eCollection 2020 Jun.
7
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
Zotero 插件